메뉴 건너뛰기




Volumn 99, Issue 10, 2014, Pages 1599-1604

Chronic lymphocytic leukemia in the elderly: Clinico-biological features, outcomes, and proposal of a prognostic model

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BETA 2 MICROGLOBULIN; CD38 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; NOTCH1 RECEPTOR; PEPTIDES AND PROTEINS; PROTEIN KINASE ZAP 70; PURINE DERIVATIVE; SF3B1 PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

EID: 84907519681     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.107326     Document Type: Article
Times cited : (55)

References (30)
  • 2
    • 78149436559 scopus 로고    scopus 로고
    • Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project
    • Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19): 3724-34.
    • (2010) Blood , vol.116 , Issue.19 , pp. 3724-3734
    • Sant, M.1    Allemani, C.2    Tereanu, C.3    De Angelis, R.4    Capocaccia, R.5    Visser, O.6
  • 3
    • 51649093353 scopus 로고    scopus 로고
    • Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
    • Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do K-A, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4): 975-80.
    • (2008) Blood , vol.112 , Issue.4 , pp. 975-980
    • Tam, C.S.1    O'Brien, S.2    Wierda, W.3    Kantarjian, H.4    Wen, S.5    Do, K.-A.6
  • 4
    • 77957664665 scopus 로고    scopus 로고
    • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial
    • Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-74.
    • (2010) Lancet , vol.376 , Issue.9747 , pp. 1164-1174
    • Hallek, M.1    Fischer, K.2    Fingerle-Rowson, G.3    Fink, A.M.4    Busch, R.5    Mayer, J.6
  • 5
    • 61449135843 scopus 로고    scopus 로고
    • Treatment of elderly patients with chronic lymphocytic leukemia
    • Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50 (2):171-8.
    • (2009) Leuk Lymphoma , vol.50 , Issue.2 , pp. 171-178
    • Eichhorst, B.1    Goede, V.2    Hallek, M.3
  • 8
    • 84891373281 scopus 로고    scopus 로고
    • Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b/2 trial
    • O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48-58.
    • (2014) Lancet Oncol , vol.15 , Issue.1 , pp. 48-58
    • O'Brien, S.1    Furman, R.R.2    Coutre, S.E.3    Sharman, J.P.4    Burger, J.A.5    Blum, K.A.6
  • 9
    • 0037406968 scopus 로고    scopus 로고
    • ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia
    • Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18):1764-75.
    • (2003) N Engl J Med , vol.348 , Issue.18 , pp. 1764-1775
    • Crespo, M.1    Bosch, F.2    Villamor, N.3    Bellosillo, B.4    Colomer, D.5    Rozman, M.6
  • 10
    • 79960036578 scopus 로고    scopus 로고
    • Wholegenome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
    • Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N, et al. Wholegenome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-5.
    • (2011) Nature , vol.475 , Issue.7354 , pp. 101-105
    • Puente, X.S.1    Pinyol, M.2    Quesada, V.3    Conde, L.4    Ordóñez, G.R.5    Villamor, N.6
  • 11
    • 84555171449 scopus 로고    scopus 로고
    • Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia
    • Quesada V, Conde L, Villamor N, Ordóñez GR, Jares P, Bassaganyas L, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2012;44 (1):47-52.
    • (2012) Nat Genet , vol.44 , Issue.1 , pp. 47-52
    • Quesada, V.1    Conde, L.2    Villamor, N.3    Ordóñez, G.R.4    Jares, P.5    Bassaganyas, L.6
  • 12
  • 13
    • 0031901577 scopus 로고    scopus 로고
    • Comorbidity and functional status are independent in older cancer patients
    • Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16(4):1582-7.
    • (1998) J Clin Oncol , vol.16 , Issue.4 , pp. 1582-1587
    • Extermann, M.1    Overcash, J.2    Lyman, G.H.3    Parr, J.4    Balducci, L.5
  • 14
    • 84866615945 scopus 로고    scopus 로고
    • Missing data in clinical studies: Issues and methods
    • Ibrahim JG, Chu H, Chen M-H. Missing data in clinical studies: issues and methods. J Clin Oncol. 2012;30(26):3297-303.
    • (2012) J Clin Oncol , vol.30 , Issue.26 , pp. 3297-3303
    • Ibrahim, J.G.1    Chu, H.2    Chen, M.-H.3
  • 15
    • 0021047301 scopus 로고
    • Analysis of survival by tumor response
    • Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1(11):710-9.
    • (1983) J Clin Oncol , vol.1 , Issue.11 , pp. 710-719
    • Anderson, J.R.1    Cain, K.C.2    Gelber, R.D.3
  • 16
    • 78349244388 scopus 로고    scopus 로고
    • Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia
    • Shanafelt TD, Rabe KG, Kay NE, Zent CS, Jelinek DF, Reinalda MS, et al. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer. 2010;116(20):4777-87.
    • (2010) Cancer , vol.116 , Issue.20 , pp. 4777-4787
    • Shanafelt, T.D.1    Rabe, K.G.2    Kay, N.E.3    Zent, C.S.4    Jelinek, D.F.5    Reinalda, M.S.6
  • 17
    • 38549168905 scopus 로고    scopus 로고
    • Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia
    • Thurmes P, Call T, Slager S, Zent C, Jenkins G, Schwager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49(1):49-56.
    • (2008) Leuk Lymphoma , vol.49 , Issue.1 , pp. 49-56
    • Thurmes, P.1    Call, T.2    Slager, S.3    Zent, C.4    Jenkins, G.5    Schwager, S.6
  • 18
    • 70350720141 scopus 로고    scopus 로고
    • First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
    • Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009; 114(16):3382-91.
    • (2009) Blood , vol.114 , Issue.16 , pp. 3382-3391
    • Eichhorst, B.F.1    Busch, R.2    Stilgenbauer, S.3    Stauch, M.4    Bergmann, M.A.5    Ritgen, M.6
  • 19
    • 84901701451 scopus 로고    scopus 로고
    • Interactions between comorbidity and treatment of chronic lymphocytic leukemia: Results of German CLL Study Group trials
    • Goede V, Cramer P, Busch R, Bergmann M, Stauch M, Hopfinger G, et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German CLL Study Group trials. Haematologica. 2014;99(6):1095-100.
    • (2014) Haematologica , vol.99 , Issue.6 , pp. 1095-1100
    • Goede, V.1    Cramer, P.2    Busch, R.3    Bergmann, M.4    Stauch, M.5    Hopfinger, G.6
  • 20
    • 84894552888 scopus 로고    scopus 로고
    • Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
    • Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101-10.
    • (2014) N Engl J Med , vol.370 , Issue.12 , pp. 1101-1110
    • Goede, V.1    Fischer, K.2    Busch, R.3    Engelke, A.4    Eichhorst, B.5    Wendtner, C.M.6
  • 21
    • 84892578245 scopus 로고    scopus 로고
    • Chronic lymphocytic leukemia in young (less than 55 years) patients: A comprehensive analysis of prognostic factors and outcomes
    • Parikh SA, Rabe KG, Kay NE, Call TG, Ding W, Schwager S, et al. Chronic lymphocytic leukemia in young (less than 55 years) patients: a comprehensive analysis of prognostic factors and outcomes. Haematologica. 2014;99(1):140-7.
    • (2014) Haematologica , vol.99 , Issue.1 , pp. 140-147
    • Parikh, S.A.1    Rabe, K.G.2    Kay, N.E.3    Call, T.G.4    Ding, W.5    Schwager, S.6
  • 22
    • 84874773634 scopus 로고    scopus 로고
    • Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: Results of sequential Cancer and Leukemia Group B studies
    • Woyach JA, Ruppert AS, Rai K, Lin TS, Geyer S, Kolitz J, et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential Cancer and Leukemia Group B studies. J Clin Oncol. 2013;31(4):440-7.
    • (2013) J Clin Oncol , vol.31 , Issue.4 , pp. 440-447
    • Woyach, J.A.1    Ruppert, A.S.2    Rai, K.3    Lin, T.S.4    Geyer, S.5    Kolitz, J.6
  • 23
    • 79953072637 scopus 로고    scopus 로고
    • Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
    • Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011;117(11):3016-24.
    • (2011) Blood , vol.117 , Issue.11 , pp. 3016-3024
    • Badoux, X.C.1    Keating, M.J.2    Wang, X.3    O'Brien, S.M.4    Ferrajoli, A.5    Faderl, S.6
  • 24
    • 84866531516 scopus 로고    scopus 로고
    • Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group
    • Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30(26): 3209-16.
    • (2012) J Clin Oncol , vol.30 , Issue.26 , pp. 3209-3216
    • Fischer, K.1    Cramer, P.2    Busch, R.3    Böttcher, S.4    Bahlo, J.5    Schubert, J.6
  • 25
    • 34249651313 scopus 로고    scopus 로고
    • CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia
    • Josefsson P, Geisler CH, Leffers H, Petersen JH, Andersen MK, Jurlander J, et al. CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood. 2007;109(11): 4973-9.
    • (2007) Blood , vol.109 , Issue.11 , pp. 4973-4979
    • Josefsson, P.1    Geisler, C.H.2    Leffers, H.3    Petersen, J.H.4    Andersen, M.K.5    Jurlander, J.6
  • 26
    • 1842328565 scopus 로고    scopus 로고
    • 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis
    • Döhner H, Stilgenbauer S, James MR, Benner A, Weilguni T, Bentz M, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood. 1997;89(7):2516-22.
    • (1997) Blood , vol.89 , Issue.7 , pp. 2516-2522
    • Döhner, H.1    Stilgenbauer, S.2    James, M.R.3    Benner, A.4    Weilguni, T.5    Bentz, M.6
  • 27
    • 84904818973 scopus 로고    scopus 로고
    • Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study
    • Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study. J Clin Oncol. 2014;32(12):1236-41.
    • (2014) J Clin Oncol , vol.32 , Issue.12 , pp. 1236-1241
    • Hillmen, P.1    Gribben, J.G.2    Follows, G.A.3    Milligan, D.4    Sayala, H.A.5    Moreton, P.6
  • 28
    • 84904431445 scopus 로고    scopus 로고
    • A phase 2 study of the selective phosphatidylinositol 3-kinase delta (PI3Kdelta) inhibitor idelalisib (GS-1101) in combination with rituximab in treatment-naïve patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
    • abstr.7005
    • O'Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of the selective phosphatidylinositol 3-kinase delta (PI3Kdelta) inhibitor idelalisib (GS-1101) in combination with rituximab in treatment-naïve patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). J Clin Oncol. 2013;31(suppl.): abstr.7005.
    • (2013) J Clin Oncol , vol.31
    • O'Brien, S.M.1    Lamanna, N.2    Kipps, T.J.3
  • 29
    • 84896480883 scopus 로고    scopus 로고
    • Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): Results of the phase III study complement 1 (OMB110911)
    • Hillmen P, Robak T, Janssens A, Govindbabu K, Grosicki S, Mayer J, et al. Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911). Blood (ASH Annual Meeting Abstracts). 2013; 122:528.
    • (2013) Blood (ASH Annual Meeting Abstracts) , vol.122 , pp. 528
    • Hillmen, P.1    Robak, T.2    Janssens, A.3    Govindbabu, K.4    Grosicki, S.5    Mayer, J.6
  • 30
    • 84899638389 scopus 로고    scopus 로고
    • Prognostic and predictive factors in patients with chronic lymphocytic leukemia: Relevant in the era of novel treatment approaches?
    • Mertens D, Stilgenbauer S. Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches? J Clin Oncol. 2014;32(9):869-72.
    • (2014) J Clin Oncol , vol.32 , Issue.9 , pp. 869-872
    • Mertens, D.1    Stilgenbauer, S.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.